Breaking News Instant updates and real-time market news.

DERM

Dermira

$33.82

1.15 (3.52%)

15:17
10/02/16
10/02
15:17
10/02/16
15:17

Dermira reports data on underarm sweating treatment DRM04

Dermira presented data, including new disease-related quality of life data, from its DRM04 Phase 3 clinical program in patients with primary axillary hyperhidrosis at the European Academy of Dermatology and Venereology Congress. In June, positive topline results from the Phase 3 ATMOS-1 and ATMOS-2 pivotal trials evaluating the safety and efficacy of DRM04, a topical anticholinergic product candidate, compared to vehicle were reported showing significant improvements in patient-reported disease severity following four weeks of treatment. New findings presented at EADV found that patients treated with DRM04 reported significant improvements in their disease-related quality of life compared to patients who received vehicle only. DRM04 showed a mean improvement from baseline in the Dermatology Life Quality Index score compared to vehicle in both the ATMOS-1 -- decrease of 8.1 vs. 4.3 -- and ATMOS-2 -- decrease of 8.6 vs. 5.0 -- clinical trials, at week 4. Dermira said it intends to present additional patient quality of life data as measured by the Axillary Sweating Daily Diary in peer-reviewed forums.

DERM Dermira
$33.82

1.15 (3.52%)

05/10/16
LEER
05/10/16
NO CHANGE
Target $46
LEER
Outperform
Dermira price target raised to $46 from $39 at Leerink
05/10/16
LEER
05/10/16
NO CHANGE
Target $46
LEER
Outperform
Dermira price target raised to $46 from $39 at Leerink
Leerink analyst Seamus Fernandez raised his price target for Dermira to $46 after upping his probability-of-success for DRM01, a topical sebum inhibitor for acne, to 90% from 75%. Top-line data showed "strongly positive" Phase IIb dose-ranging efficacy and safety, Fernandez tells investors in a post-earnings research note. He points out Dermira plans to advance DRM01 into Phase III in the first half of 2017. The analyst keeps an Outperform rating on the shares.
06/02/16
LEER
06/02/16
NO CHANGE
Target $47
LEER
Outperform
Dermira DRM04 results 'broadly positive,' says Leerink
Following top-line data from the two Phase 3 studies of Dermira's DRM04 for the treatment of hyperhidrosis, Leerink analyst Seamus Fernandez is raising his overall probability of success from 75% to 85%. The analyst sees the new data as "broadly positive," and notes that Dermira remains one of his Small-/Mid-Cap Top-Picks for 2016. Fernandez reiterates an Outperform rating on the stock and raised his price target on the shares to $47 from $46.
09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.